BRUSSELS, BELGIUM--(MARKET WIRE)--Jul 26, 2007 --
Revenue increased to 1.86 billion euro driven by strong performance of Keppra® and Xyzal®
Underlying profitability (recurring EBITDA) increased by 14%* to 485 million euro
Synergy target increased from 300 million euro to 380 million euro
